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Abstract
Purpose: To evaluate the daily dose delivered to the patients
using daily imaging.
Methods: Thirty (n = 30) patients that were previously treated
in our clinic (10 prostate, 10 SBRT lung and 10 abdomen)
were used in this study. The patients’ plans were optimized
and calculated using the Pinnacle treatment planning system.
The daily CBCT scans were retrieved and imported into the
Velocity and RayStation software along with the corre-
sponding planning CTs, structure sets and 3D dose distribu-
tions. In addition, the critical structures were contoured on
each CBCT by the prescribing physician and were included in
the evaluation of the daily delivered dose. After registering
each CBCT scan to the planning CT using deformable regis-
tration, the dose volume histograms (DVH) for the organs at
risk (OAR) and the respective planning target volumes (PTV)
were calculated in Velocity and Raystation.
Results: For the prostate patients, we observed daily volume
changes for the bladder, rectum and sigmoid. The DVH
analysis for those patients showed variation in the sparing of
the critical structures while PTV coverage showed no signif-
icant changes. Similar results were observed for patients with
abdominal targets. In contrast, in SBRT lung patients, the
DVH for the critical structures and the PTV were comparable
to those from the initial treatment plan. By using daily CBCT
dose reconstruction, we proved PTV coverage for prostate
and abdominal targets is adequate. However, there is signifi-
cant dosimetric change for the OAR. These changes were
random with no apparent trending. For lung SBRT patients,
the delivered daily dose for both PTV and OAR is comparable
to the planned dose with no significant differences.
Conclusion: Daily tracking of the delivered dose is feasible.
The doses can be evaluated only if the OARs have been seg-
mented taken into account any daily anatomical changes and
not by deformation of the structures along.
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TABLE 1: Dose (Gy) and Volume (cc) from Velocity. The volumes are mapped from the planning CT to the CBCT using deformable registration.
(The ‘Plan’ dose and volume are not included in the average and standard deviation.)
Bladder Rectum Sigmoid Prostate PTV
Volume Dose Volume Dose Volume Dose Volume Dose
CBCT 1 107.3 26.06 49 23.26 54.3 15.73 233.9 45.88
CBCT 2 107 31.32 50.1 21.51 54.6 21.85 234.3 45.69
CBCT 3 107.2 34.28 49.5 20.61 54.7 28.72 233.6 45.73
CBCT 4 107.1 28.74 49.2 22.84 54.3 22.98 234 45.89
CBCT 5 107.3 29 49.4 25.44 53.9 27.45 234.9 45.87
Plan 107.2 26 49.4 21.66 54.5 18.34 234 45.93
Average 107.18 29.23 49.43 22.55 54.38 22.51 234.12 45.83
Std. Dev. 0.13 3.09 0.42 1.85 0.31 5.15 0.49 0.09
TABLE 2:Dose (Gy) and volume (cc) from RayStation. The volumes are mapped from the planning CT to the CBCT using deformable registration.
(The ‘Plan’ dose and volume are not included in the average and standard deviation.)
Bladder Rectum Sigmoid Prostate PTV
Volume Dose Volume Dose Volume Dose Volume Dose
CBCT 1 106.27 27 48.62 19.5 53.26 15.5 232.59 44.5
CBCT 2 106.27 18.25 48.62 21 53.26 10 232.59 42.5
CBCT 3 106.27 22.75 48.62 20.5 53.26 13 232.59 44.25
CBCT 4 106.27 20.75 48.62 22 53.26 9.25 232.59 43.5
CBCT 5 106.27 18.25 48.62 21 53.26 10 232.59 44.25
Plan 106.65 26.01 48.96 20.84 53.55 18.08 232.95 45.92
Average 106.33 21.40 48.68 20.80 53.31 11.55 232.65 43.80
Std. Dev. 0.00 3.66 0.00 0.91 0.00 2.64 0.00 0.82
FIG. 1: DVH of CBCT 1 from Ray Station using deformable registration.
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